No clinical trial has directly tested whether vaping causes bacterial vaginosis, so the honest answer is that we do not have proof. What we do have is a well-established link between cigarette smoking and BV, a growing understanding of how nicotine and other e-cigarette ingredients damage the body’s protective barriers, and a clear biological rationale for why vaping could shift vaginal health in the wrong direction. The gap in the research is real, but the pieces fit together closely enough to take seriously.
The Strong Connection Between Smoking and BV
Before getting to vaping, it helps to understand what traditional cigarettes do. Researchers have consistently found that women who smoke are significantly more likely to develop BV than women who do not. One well-known study found that roughly half of women with BV were smokers, compared to about a third of women without BV, and after adjusting for sexual behavior, reproductive history, and alcohol use, smoking roughly tripled the odds of having BV. The study also found a dose-response pattern: the more a woman smoked, the higher her risk.1PubMed. Bacterial vaginosis and smoking
This is not an isolated finding. Multiple studies over the past two decades have arrived at similar conclusions. What makes it relevant to vaping is the question it raises: is it the act of burning tobacco that causes the problem, or is it something in the smoke that reaches the vaginal environment through the bloodstream? If the answer is the latter, then any nicotine delivery system, including e-cigarettes, could carry similar risks.
How Nicotine Ends Up in the Vaginal Environment
One of the more striking findings in this area is that nicotine and its primary breakdown product, cotinine, do not stay in the lungs. After being absorbed into the bloodstream, cotinine concentrates in cervical mucus, sometimes reaching higher levels there than in the blood itself.2Nature. Cigarette smoking is associated with an altered vaginal tract metabolomic profile This means the vaginal and cervical tissues are being exposed directly to nicotine metabolites, not just receiving some distant downstream effect of smoking.
This matters because the vaginal ecosystem depends on a delicate balance. A healthy vaginal microbiome is typically dominated by Lactobacillus bacteria, which produce lactic acid and keep the environment acidic enough to suppress harmful organisms. When that balance tips, BV-associated bacteria proliferate, the pH rises, and symptoms like discharge and odor follow. Nicotine’s presence in cervical mucus gives it a direct route to interfere with that balance.
A pilot study comparing the vaginal microbiomes of smokers and non-smokers found dramatic differences. Half of the smokers had vaginal communities classified as low-Lactobacillus, meaning the protective bacteria were largely absent, compared to only about 15% of non-smokers. Smokers were also far less likely to have communities dominated by the particularly beneficial species Lactobacillus crispatus: only 30% of smokers had L. crispatus-dominated communities versus 65% of non-smokers.3PubMed Central. Association between cigarette smoking and the vaginal microbiota: a pilot study Those are large differences, and the statistical modeling suggested that even after accounting for douching and number of sexual partners, women with low-Lactobacillus communities were dramatically more likely to be smokers.
The logical leap from cigarettes to vaping here is straightforward: e-cigarettes also deliver nicotine, and nicotine still enters the bloodstream and reaches cervical mucus regardless of whether it arrives from burning tobacco or from an aerosolized liquid. Cotinine does not care about its source. If nicotine exposure is a primary driver of the smoking-BV link, then vaping would carry the same risk through the same pathway.
What Propylene Glycol and Vegetable Glycerin Do to Tissue Barriers
Vaping introduces more than nicotine. The base liquids in most e-cigarettes are propylene glycol (PG) and vegetable glycerin (VG), which create the visible aerosol cloud. These are generally considered safe for ingestion at low levels, but inhaling them as aerosol is a different exposure route, and the research on what they do to living cells is less reassuring.
When airway epithelial cells were exposed to PG and VG in laboratory settings, the chemicals inhibited the cells’ ability to take up glucose and disrupted mitochondrial energy production. They also caused cells to shrink and reduced the integrity of the epithelial barrier, essentially making the tissue layer more permeable to substances that should not pass through easily.4PubMed Central. E-cigarette constituents propylene glycol and vegetable glycerin decrease glucose uptake and its metabolism in airway epithelial cells in vitro When researchers puffed PG/VG vapor directly onto primary human airway cells to simulate actual vaping, they saw the same glucose transport reductions.
Separate experiments found that PG/VG aerosols also caused measurable cell damage in human nasal epithelial cells, as indicated by increased release of a cellular damage marker, even without nicotine present.5Scientific Reports. Propylene glycol and vegetable glycerin e-cigarette aerosols impact mucociliary function and cause cytotoxicity in human airway epithelium
These studies tested airway tissue, not vaginal tissue. That is an important caveat. But the mechanism they describe, barrier disruption caused by the base ingredients of e-liquid, is relevant to any mucosal surface. Epithelial barriers throughout the body share similar architecture: tight junctions holding cells together, mucus layers on top, and the same basic toolkit of glucose transporters and structural proteins. When a chemical impairs barrier function in one mucosal tissue, the concern that it could do the same elsewhere is grounded in biology, not speculation. And a compromised vaginal epithelial barrier would be less able to maintain the acidic, Lactobacillus-friendly environment that keeps BV at bay.
E-Cigarettes and Barrier Disruption Beyond PG/VG
A systematic review examining the impact of e-cigarettes on human barrier systems concluded that e-cigarettes, regardless of whether the liquid contains nicotine, cause oxidative stress, inflammation, and disruption of tight junction proteins, all of which impair barrier function.6PubMed. Assessing the impact of e-cigarettes on human barrier systems That finding deserves emphasis: even nicotine-free vaping caused damage. This means the PG/VG base, the flavorings, or the aerosol exposure itself can cause harm independently of nicotine.
Research using human bronchial epithelial cells showed that e-cigarette nicotine aerosol caused a significant decrease in the structural integrity of tight junctions, the protein complexes that seal cells together. Adding cinnamon or menthol flavoring on top of nicotine made the damage worse, suggesting the components act together to compound the disruption.7PubMed Central. Electronic cigarette exposure disrupts airway epithelial barrier function and exacerbates viral infection The same study found that barrier-compromised cells were more vulnerable to viral infection, which illustrates a broader principle: once the barrier is weakened, the tissue becomes susceptible to a range of problems it would normally resist.
For vaginal health, the implication is that if e-cigarette ingredients circulating in the blood reach mucosal tissues and degrade tight junctions there too, the vaginal epithelium could become less resilient. A less intact barrier means less effective acid production, easier colonization by BV-associated organisms, and a harder time maintaining a stable Lactobacillus community.
Flavorings Can Suppress Beneficial Bacteria
Most vapers do not use flavorless e-liquid. The flavoring chemicals added to make e-liquids taste like menthol, cinnamon, fruit, and dessert are themselves biologically active. Lab research found that flavoring chemicals in e-liquids rapidly impaired epithelial barrier function in human lung cells and triggered inflammatory responses.8PubMed Central. Inflammatory Response and Barrier Dysfunction by Different e-Cigarette Flavoring Chemicals Identified by Gas Chromatography-Mass Spectrometry in e-Liquids and e-Vapors on Human Lung Epithelial Cells and Fibroblasts
There is also an antimicrobial angle. When researchers tested flavored e-liquids against common oral commensal Streptococcus bacteria (the beneficial bacteria that normally colonize the mouth), they found dose-dependent inhibition of bacterial growth, with menthol, cinnamon, and strawberry flavors being particularly potent at suppressing these organisms.9Frontiers in Physiology. Flavorless vs. Flavored Electronic Cigarette-Generated Aerosol and E-Liquid on the Growth of Common Oral Commensal Streptococci The bacteria tested were oral species, not vaginal Lactobacillus. But the finding reveals something important about flavoring chemicals: they are not inert passengers. They actively kill bacteria, and they do so at concentrations present in commercial e-liquids.
If flavoring compounds reach the vaginal environment through the bloodstream or through systemic effects on mucous membranes, even at lower concentrations than in the mouth, they could selectively suppress the Lactobacillus species that protect against BV. Lactobacillus species vary in their resilience, and L. crispatus, the one most strongly associated with vaginal health, is already less common in smokers. Adding another chemical stressor on top of nicotine could push a borderline-stable community over the edge.
Why No One Has Run the Definitive Study Yet
Given all this biological plausibility, it is reasonable to wonder why no large clinical study has directly measured BV rates in vapers versus non-vapers. Part of the reason is practical: vaping is relatively new compared to cigarettes, and the research pipeline is still catching up. Most of the funding and attention around e-cigarettes has gone toward respiratory and cardiovascular effects, which are more immediately life-threatening. Vaginal health, while affecting millions of people, receives comparatively little research investment in general.
There are also methodological challenges. Isolating the effect of vaping on BV would require controlling for sexual behavior, hygiene practices, hormonal contraception use, antibiotic history, and whether participants also smoke cigarettes. Many vapers are former or current smokers, which makes it hard to separate the effects of each exposure. And recruiting large enough cohorts of exclusive vapers who have never smoked takes time as the demographics of vaping shift.
The result is a gap: the mechanistic evidence points in one direction, the epidemiological data on cigarettes is strong, and the clinical confirmation for e-cigarettes specifically has not arrived. This is a common pattern in emerging health research. It does not mean the risk is not real; it means the formal proof is lagging behind the biology.
What Happens After Quitting
Some of the most interesting data comes from a small cessation study that tracked women’s vaginal microbiomes as they stopped smoking. Of four women who completed the 12-week program, one showed a clear response to quitting. She entered the study with a low-Lactobacillus community and high Nugent scores (a clinical measure of BV). At around week 10, after finishing both the smoking cessation program and the nicotine patch protocol, her vaginal community shifted to Lactobacillus-dominated types, and her Nugent scores dropped. She also reported that her intermittent vaginal odor and discharge resolved in the final two weeks, when she had fully stopped both smoking and nicotine replacement.3PubMed Central. Association between cigarette smoking and the vaginal microbiota: a pilot study
This is a single case within a very small study, so it cannot be generalized. But it is suggestive in two ways. First, it hints that the vaginal microbiome can recover once the nicotine exposure stops, which is encouraging. Second, the recovery coincided not just with quitting cigarettes but with finishing the nicotine patch as well, which reinforces the idea that nicotine itself, not just the combustion products in cigarette smoke, plays a role in disrupting vaginal flora.
For vapers, this is a nuanced signal. If you are vaping nicotine and concerned about vaginal health, switching from cigarettes to vaping might remove some harmful combustion byproducts but would not eliminate the nicotine pathway. Full cessation of nicotine would be necessary to remove that particular driver, though we do not yet know how long recovery takes or how reliably the microbiome bounces back across different individuals.
Other Factors That Interact with Vaping
BV is not caused by a single factor. It tends to result from a combination of influences that collectively destabilize the vaginal microbiome. Douching, for instance, is one of the strongest behavioral risk factors, and it was controlled for in the smoking studies precisely because it so powerfully affects vaginal flora. New or multiple sexual partners shift the microbial landscape. Antibiotics, while treating infections, can wipe out protective Lactobacillus along with the target pathogen. Hormonal fluctuations from the menstrual cycle, pregnancy, or contraception all influence which bacterial communities thrive.
Vaping likely does not act alone in any of these scenarios. Its potential contribution would be layered on top of whatever other risk factors a person carries. Someone with an already-marginal Lactobacillus community, perhaps due to recent antibiotic use or hormonal changes, might be more vulnerable to the additional push that nicotine or flavoring chemicals provide. Someone with a robust L. crispatus-dominated community might tolerate the exposure without noticeable effect. This kind of interaction is exactly what makes BV so frustrating for the people who experience recurrent episodes: the triggers are cumulative and personal, not a single identifiable cause.
If you are dealing with recurrent BV and you vape, the evidence is not yet strong enough for anyone to say vaping is definitely your problem. But it is strong enough that reducing or eliminating nicotine exposure is a reasonable step to discuss with a healthcare provider, particularly if other modifiable risk factors have already been addressed.
Nicotine-Free Vaping and the Remaining Unknowns
An increasingly common question is whether nicotine-free e-cigarettes carry the same concern. The systematic review of e-cigarette effects on barrier systems found that barrier disruption occurred even without nicotine in the liquid, driven by the base solvents and flavorings alone.6PubMed. Assessing the impact of e-cigarettes on human barrier systems This suggests that switching to zero-nicotine pods would not eliminate all potential risk, though it would remove the nicotine-specific pathway (the cotinine accumulation in cervical mucus and its effects on vaginal Lactobacillus).
How much residual risk comes from PG, VG, and flavorings alone, once nicotine is removed, is genuinely unknown for vaginal health. The airway studies suggest these ingredients cause real cellular damage, but whether they reach the vaginal environment at high enough concentrations to matter after being absorbed through the lungs, entering the bloodstream, and arriving at a distant mucosal surface is a question no one has measured. It is biologically possible but unquantified.
The situation with flavorings is particularly murky because the chemical composition varies wildly between brands and even between batches. Cinnamon-flavored e-liquids, for example, typically contain cinnamaldehyde, which is a known irritant and antimicrobial agent. Menthol has its own biological activity. But “strawberry” or “mango” flavoring from different manufacturers might contain entirely different chemical mixtures. Without standardized testing of how these compounds affect vaginal flora specifically, any claim about a particular flavor’s risk would be speculation.
What can be said is that the “it’s just water vapor” framing that surrounded early e-cigarette marketing has been thoroughly dismantled by the research. E-cigarette aerosol contains biologically active chemicals that affect living cells in measurable ways. Whether those effects extend to vaginal health at clinically meaningful levels is the question the next generation of studies needs to answer.